AbbVie Inc.

AbbVie is a research-based pharmaceutical company. It spun off of Abbott Laboratories in 2013. The company has had a successful start in its first five years in the industry. Its blockbuster drug Humira brought in billions. But AbbVie has also faced lawsuits over some of its largest selling products.

AbbVie logo
AbbVie Facts
  1. Established 2013
  2. CEO Richard A. Gonzalez
  3. Headquarters Lake Bluff, North Chicago, Illinois
  4. Size About 29,000 employees (2017)
  5. 2018 Sales $29.61 billion
  6. Subsidiaries Pharmacyclics
Fact-Checked

Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

AbbVie is a research-based pharmaceutical company. It started as a spinoff of the long-established health care corporation Abbott Laboratories.

AbbVie was an immediate success, netting $18.8 billion in sales in its first year. This was largely due to the strength of its blockbuster drug Humira.

But, injured patients are suing AbbVie over the safety of some of the company’s popular drugs. Lawsuits blame Humira, AndroGel and Depakote for serious injuries and death.

About AbbVie

AbbVie employs about 29,000 people in 75 countries. Its headquarters is in Lake Bluff, Illinois, which is a part of the Chicago metropolitan area.

Richard A. Gonzalez is AbbVie’s CEO. The company’s products brought in total revenues of $28.2 billion in 2017. The drugmaker focuses on immunology, oncology, neuroscience and virology.

AbbVie History

AbbVie officially separated from Abbott Laboratories on Jan. 1, 2013. Abbott wanted to concentrate on medical devices such as heart stents. This allowed AbbVie to focus on research-based pharmaceuticals.

AbbVie’s Notable Pharmaceutical Accomplishments
  • April 2013
    AbbVie releases its first branded product (Humira)
  • November 2014
    Brands serve more than 30 million people worldwide
  • December 2014
    First AbbVie-created medicine Viekira Pak gains U.S. approval
  • January 2105
    FDA approves Parkinson’s disease medicine Duopa
  • September 2015
    Humira receives the first and only approval to treat hidradenitis suppurativa, a chronic inflammatory skin disease
  • March 2016
    AbbVie gains new approvals for Imbruvica and Venclexta/Venclyxto
  • April 2016
    AbbVie acquires Stemcentrx to expand oncology presence
  • June 2016
    FDA approves Humira to treat an immune-mediated disease that can impair vision
  • June 2017
    Reputation Institute names AbbVie 2017’s most reputable pharmaceutical company
  • July 2017
    Maviret/Mavyret receives approval
  • October 2017
    DA grants AbbVie priority review of investigational treatment for endometriosis management

AbbVie Products

AbbVie makes more than 30 products and has more than 50 drugs in development. Several of the company’s pharmaceuticals rake in billions annually. These include Humira, Imbruvica and Viekira.

By far, AbbVie’s biggest sales generator is Humira. Doctors prescribe the drug to treat arthritis, psoriasis and Crohn’s disease. It accounts for more than half of AbbVie’s total annual sales.

AbbVie Pharmaceutical Products
Depakote
Anti-seizure medication
Humira
Drug for arthritis, Crohn’s disease
Vicodin
Pain reliever
Marinol
Synthetic cannabinoid (man-made delta-9-tetrahydrocannabinol or THC)
Tricor
Treats high cholesterol and triglycerides (fat)
Biaxin
Macrolide antibiotic
Nimbex
Muscle relaxer
Norvir
Antiretroviral (HIV) medication
Synthroid
Thyroid hormone
Zemplar
Man-made form of vitamin D (treats chronic kidney failure)
Ultane
Inhaled anesthetic

AbbVie’s Humira Patent Fight

Humira is the world’s top-selling prescription drug, according to The New York Times.

The drug brought in $16 billion for AbbVie in 2016. Estimates for 2017 show increases of more than 15 percent in the U.S. and 6.5 percent abroad.

AbbVie is trying to block generic competition by filing new patents. AbbVie has filed more than 70 new patents on Humira.

“Any company seeking to market a biosimilar version of Humira will have to contend with this extensive patent estate, which AbbVie intends to enforce vigorously.”

Source: Richard A. Gonzalez, AbbVie Chairman and Chief Executive Officer, told to The New York Times

In May 2017, AbbVie lost one round to the company Coherus. But according to Fortune, other patents should protect AbbVie’s sales through 2022.

Medical Marijuana and AbbVie

Some analysts classify AbbVie as a maker of medical marijuana.

AbbVie’s Marinol was the first FDA-approved cannabis drug. Solvay Pharmaceuticals developed the drug. Abbott acquired Solvay’s pharmaceutical division in 2010 and took on Marinol as well.

Marinol Oral Drug
Marinol was the first FDA-approved cannabis drug.

Doctors prescribe Marinol to patients with nausea and vomiting from cancer. People with AIDs use it to combat lack of appetite.

Its active ingredient is a synthetic cannabinoid – man-made delta-9-tetrahydrocannabinol or THC. This main ingredient gives the drug its effects.

Abbvie doesn’t release Marinol’s sales numbers. This leads analyst to believe it’s not very profitable. But future developments on legalization may change the long-term outlook of the drug.

AbbVie Lawsuits and Settlements

AbbVie faces thousands of personal injury lawsuits. People blame the company’s products for serious injuries and deaths. The lawsuits accuse the company of failing to warn about its drugs’ risks.

The company’s biggest seller, Humira, is the subject of some of these lawsuits. AbbVie’s testosterone replacement treatment AndroGel and its anti-seizure medication Depakote have also led to lawsuits.

Humira Lawsuits

Humira lawsuits blame the drug for fungal infections, nerve damage, and an increased risk of cancer in children and adolescents. In 2013, a jury ordered AbbVie to pay $2.24 million to a patient who suffered from a fungal infection. Some patients have died from these infections, according to the FDA.

AndroGel Lawsuits

More than 7,750 men have filed testosterone lawsuits against AbbVie and other manufacturers of testosterone replacement therapy products. Nearly 6,000 remained pending in federal court in Illinois in June 2018. AndroGel lawsuits blame the product for blood clots, heart attack, stroke and sudden death.

AndroGel Packaging
AndroGel lawsuits say AbbVie marketed the therapy for the natural signs of aging, while downplaying the risks.
Did you suffer cardiac side effects or stroke after taking AndroGel? Get a Free Case Review

Depakote Lawsuits

Depakote lawsuits say children suffered birth defects after their mothers took Depakote during pregnancy. AbbVie assumed all rights and responsibilities for Depakote when it separated from Abbott. In June 2018, a judge halted more than 600 lawsuits so lawyers on both sides could discuss settlements.

AbbVie Recalls

AbbVie has had to recall some of its products. Reasons include labeling errors, possible contamination and harmful drug effects.

Its multiple sclerosis drug Zinbryta was pulled from the shelves altogether in March 2018. It led to the deaths of three patients. The drug was a joint venture with Biogen.

Notable AbbVie Recalls
  • 2013
    Product recalled
    Synthroid

    Reason for recall
    Labeling error; a bottle contained a lower dose
  • 2015
    Product recalled
    Zemplar injection

    Reason for recall
    Single vial contained a free-flowing glass particle
  • 2018
    Product recalled
    Zinbryta (MS drug)

    Reason for recall
    Reports of serious inflammatory brain disorders, including encephalitis and meningoencephalitis, and patient deaths; possible severe immune reactions affecting other body organs

Please seek the advice of a medical professional before making health care decisions.

30 Cited Research Articles

  1. Forbes. (2018, June) The World’s Biggest Public Companies. #137 AbbVie. Retrieved from https://www.forbes.com/companies/abbvie/
  2. Mukherjee, S. (2017, May 18). The World’s Best-Selling Drug Just Lost a Key Patent Battle. Retrieved from http://fortune.com/2017/05/18/humira-abbvie-patent-biotech
  3. McCarthy, N. (2017, April). The Top 15 Countries For Military Expenditure in 2016. [Infographic]. Retrieved from https://www.forbes.com/sites/niallmccarthy/2017/04/24/the-top-15-countries-for-military-expenditure-in-2016-infographic/#2b63053943f3
  4. AbbVie. (2013, January 30). AbbVie Issues Inaugural Full-Year Outlook for 2013. Retrieved from https://news.abbvie.com/news/abbvie-issues-inaugural-full-year-outlook-for-2013.htm
  5. AbbVie. (n.d.) About AbbVie. Retrieved from https://www.abbvie.com/our-company/about-abbvie.html
  6. Japsen, B. (2016, July 21). How Abbvie’s Humira Undercuts The Drug Industry Price Defense. Retrieved from https://www.forbes.com/sites/brucejapsen/2016/07/21/how-abbvies-humira-undercuts-the-drug-industry-price-defense/#370788f36821
  7. Pollack, A. (2016, July 15). Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions. Retrieved from https://www.nytimes.com/2016/07/16/business/makers-of-humira-and-enbrel-using-new-drug-patents-to-delay-generic-versions.html?_r=0
  8. Reputation Institute. (2017, May 31). AbbVie, Novo Nordisk and Takeda Have The Best Reputations Among Pharma Companies According to Reputation Institute Global Pharma Reptrak Study. Retrieved from https://www.reputationinstitute.com/CMSPages/GetAzureFile.aspx?path=~\media\media\documents\globalpharmareptrak2017-pressrelease_170530c.pdf&hash=54603b4b436df68b89756e760187da520193869af5f7d7468c6091652e6fb455
  9. De La Merced, M.J. and Japsen, B., (2011, October 19). Abbott Labs to Split Into 2 Companies. Retrieved from https://dealbook.nytimes.com/2011/10/19/abbott-to-split-into-two/?_r=1
  10. Teichert, E. (2017, February 3). Jury clears Abbott and AbbVie in Depakote birth defect trial. Retrieved from http://www.reuters.com/article/products-depakote-idUSL1N1FP010
  11. Raymond, N. (2017, June 9). AbbVie must pay $15 million in Depakote birth-defect trial: jury. Reuters. Retrieved from https://www.reuters.com/article/us-abbvie-lawsuit-idUSKBN1902LK
  12. English-Bowers, M. (2016, January 24). AbbVie, Abbott Laboratories allegedly knew Depakote could cause birth defects. Retrieved from http://madisonrecord.com/stories/510659472-abbvie-abbott-laboratories-allegedly-knew-depakote-could-cause-birth-defects
  13. Marinol. (n.d.). About Marinol Capsules. Retrieved from http://www.marinol.com/patient/about-marinol
  14. Lachard, S. (2017, June 1). Ask the DMO: Is AbbVie (NYSE: ABBV) A Marijuana Stock? Retrieved from https://www.dailymarijuanaobserver.com/single-post/2017/06/01/ABBV-Ask-The-Daily-Marijuana-Observer-Is-AbbVie-a-Marijuana-Stock
  15. Bloomberg. (2017, June 5). AbbVie’s testosterone gel under microscope as first trial begins. Retrieved from http://www.chicagobusiness.com/article/20170605/NEWS03/170609944/testosterone-gel-from-abbvie-trials-begin
  16. King, S. (2013, January 28). Best Selling Drugs of All Time; Humira Joins The Elite. Retrieved from https://www.forbes.com/sites/simonking/2013/01/28/the-best-selling-drugs-of-all-time-humira-joins-the-elite/#7a16974f5110
  17. Herper, M. (2016, September 14). Price Increases To Help Drug Hit $15 Billion in Sales. Retrieved from https://www.forbes.com/sites/matthewherper/2016/09/14/price-increases-to-help-create-worlds-first-15-billion-medicine/#751d0f86491f
  18. Holdman, J. (2013, May 10). Mandan family awarded $2.24 million in drug lawsuit. Retrieved from http://bismarcktribune.com/news/local/mandan/mandan-family-awarded-million-in-drug-lawsuit/article_a6cb2f98-b9c3-11e2-bae1-0019bb2963f4.html
  19. U.S. Food and Drug Administration. (2015, July 8) Information on Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimizia, and Simponi). Retrieved from https://www.fda.gov/Drugs/DrugSafety/ucm109340.htm
  20. Humira. (n.d.). Learn how Humira works for moderate to severe Crohn’s disease. Retrieved from https://www.humira.com/crohns/how-humira-works-for-crohns
  21. Bajaj, S. (2016, May 18). 4 Top Stocks in the Growing Medical Marijuana Industry. Retrieved from https://www.thestreet.com/story/13575404/1/4-best-stocks-in-the-thriving-medical-marijuana-industry.html
  22. AbbVie. (n.d.). Our Journey of Impact. Retrieved from https://www.abbvie.com/landing/our-journey-of-impact.html
  23. AbbVie. (n.d.). Products. Retrieved from https://www.abbvie.com/our-science/products.html
  24. Elejalde-Ruiz, A. (2018, February 9). AbbVie, facing thousands of lawsuits about its AndroGel testosterone supplement, notches a significant win. Chicago Tribune. Retrieved from http://www.chicagotribune.com/business/ct-biz-abbvie-androgel-lawsuits-20180205-story.html
  25. U.S. Judicial Panel on Multidistrict Litigation. (2018, May 15). MDL Statistics Report – Distribution of Pending MDL Dockets by District. Retrieved from http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-May-15-2018.pdf
  26. ASD Healthcare. (2015, July 10). Urgent: AbbVie, Inc. Issues Market Withdrawal for One Lot of Zemplar Injection. Retrieved from https://www.asdhealthcare.com/AsdHealthcare/media/AsdLibrary/pdfs/News/Abbvie-Zemplar-Recall-Full-Web-Notice-Copy.pdf
  27. Helfand, C. (2018, March 7). EMA suspends, recalls AbbVie and Biogen’s doomed MS drug Zinbryta. Fierce Pharma. Retrieved from https://www.fiercepharma.com/pharma/ema-suspends-recalls-abbvie-and-biogen-s-doomed-ms-drug-zinbryta
  28. The Associated Press. (2013, January 11). AbbVie recalling thyroid drug. Yahoo. Retrieved from https://www.yahoo.com/news/abbvie-recalling-thyroid-drug-234915375.html
  29. AbbVie. (2018, January 26). AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results. Retrieved from https://news.abbvie.com/news/abbvie-reports-full-year-and-fourth-quarter-2017-financial-results.htm
  30. AbbVie. (2017, October). Marinol (dronabinol) capsules. Retrieved from http://www.marinol.com/
View All Sources
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(888) 645-1617

To contact Drugwatch Managing Editor Kevin Connolly, call (855) 839-9780.